NCT06920004View on ClinicalTrials.gov

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

PHASE3RecruitingINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

August 22, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2030

Conditions
Chronic Inflammatory Demyelinating PolyneuropathyCIDPCIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
BIOLOGICAL

empasiprubart

Intravenous infusion of empasiprubart

BIOLOGICAL

IVIg

Intravenous infusion of IVIg

OTHER

empasiprubart-placebo

A placebo resembling the empasiprubart treatment

OTHER

IVIg-placebo

A placebo resembling the IVIg treatment

Trial Locations (1)

77094

RECRUITING

NeuroCarePlus, Houston

Sponsors

Lead Sponsor

argenx
All Listed Sponsors
lead

argenx

INDUSTRY

NCT06920004 - A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP | Biotech Hunter | Biotech Hunter